2 completed, 1 active not recruiting, 1 approved for marketing, 1 unknown. 2 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow viltolarsen: new trials by email Literature Review of viltolarsen trials Research Report on viltolarsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53) Viltolarsen - Duchenne Muscular Dystrophy | Phase 2 | Completed | NS Pharma, Inc. | 20 | 2021-07-01 | 2024-08-20 |
| Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) Viltolarsen - Duchenne Muscular Dystrophy | Phase 4 | Active not recruiting | NS Pharma, Inc. | 9 | 2021-06-10 | 2022-10-19 |
| Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) Viltolarsen - Duchenne Muscular Dystrophy | Phase 3 | Unknown | NS Pharma, Inc. | 74 | 2021-04-13 | 2024-02-14 |
| Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) Viltolarsen, Placebo - Duchenne Muscular Dystrophy | Phase 3 | Completed | NS Pharma, Inc. | 77 | 2020-04-14 | 2024-12-11 |
| The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation viltolarsen - Muscular Dystrophy, Duchenne, DMD | Approved for marketing | NS Pharma, Inc. | 2020-08-18 |
Muscular Dystrophy, Duchenne (5) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Muscular Diseases (1) · Muscular Disorders, Atrophic (1) · Muscular Dystrophies (1) · Musculoskeletal Diseases (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1)
NS Pharma, Inc. (5)
Canada (3) · China (3) · Italy (3) · Russia (3) · Spain (3) · Turkey (Türkiye) (3) · United States (3) · Australia (2) · Chile (2) · Greece (2) · Mexico (2) · Netherlands (2) · New Zealand (2) · Norway (2) · South Korea (2)